Abstract
Background
Non-anatomic resection (NAR) has emerged as a safe and effective technique for resection of colorectal liver metastases (CRLM). More recently, RAS mutation has been identified as an important indicator of aggressive disease, which may require anatomic resection (AR). In this retrospective study, we compared the long-term outcomes of AR versus NAR in CRLM patients with and without RAS mutations.
Methods
Patients with known RAS mutation status who underwent AR or NAR for CRLM between 2006 and 2016 were included. Differences in baseline characteristics were adjusted using 1:1 propensity score matching, including the most important factors that contributed to the decision to use the resection technique. Overall survival (OS), recurrence-free survival (RFS), and liver-specific recurrence-free survival (L-RFS) were compared between cohorts.
Results
Among 622 total patients, 338 (54%) underwent AR and 284 (46%) NAR. There was no difference in OS or L-RFS between the AR and NAR groups, regardless of mutation status. There was increased RFS in the RAS WT patients with NAR (P = 0.034), but no difference in RFS in the whole cohort or RAS mutant group. After propensity score matching, 360 patients were analyzed, and no differences in OS, RFS, or L-RFS rates were seen between any groups. There was also no difference in margin recurrence.
Conclusions
Similar outcomes can be achieved with both AR and NAR, regardless of RAS mutation status. These data do not support a universal requirement for AR in RAS mutant CRLM when not necessary to achieve an R0 resection.
Similar content being viewed by others
References
Moris D, Ronnekleiv-Kelly S, Rahnemai-Azar AA, Felekouras E, Dillhoff M, Schmidt C, et al. Parenchymal-sparing versus anatomic liver resection for colorectal liver metastases: A systematic review. J Gastrointest Surg 2017;21:1076–85.
Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey JN, Conrad C. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg 2016;263:146–52.
Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 2001;181:153–9.
Stewart GD, O'Suilleabhain CB, Madhavan KK, Wigmore SJ, Parks RW, Garden OJ. The extent of resection influences outcome following hepatectomy for colorectal liver metastases. Eur J Surg Oncol 2004;30:370–376.
Gold JS, Are C, Kornprat P, Jarnagin WR, Gonen M, Fong Y, et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 2008;247:109–117.
Lalmahomed ZS, Ayez N, van der Pool AE, Verheij J, JN IJ, Verhoef C. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World J Surg 2011;35:656–661.
Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013;258:619–626.
Margonis GA, Buettner S, Andreatos N, Sasaki K, Ijzermans JNM, et al. Anatomical resections improve disease-free survival in patients with KRAS-mutated colorectal liver metastases. Ann Surg 2017;266:641–649.
Renaud S, Seitlinger J, Lawati YA, Guerrera F, Falcoz PE, et al. Anatomical resections improve survival following lung metastasectomy of colorectal cancer harboring KRAS mutations. Ann Surg 2018; https://doi.org/10.1097/SLA.0000000000002829.
Couinaud C. [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver]. Presse Med 1954;62:709–712.
The Brisbane 2000 Terminology of Liver Anatomy and Resections. Terminology Committee of the International Hepato-Pancreato- Biliary Association. HPB. 2000;2 (3): 333–39.
Brudvik KW, Mise Y, Conrad C, Zimmitti G, Aloia TA, et al. Definition of readmission in 3,041 patients undergoing hepatectomy. J Am Coll Surg 2015;221:38–46.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.
DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, et al. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 2000;4:178–184.
Matsumura M, Mise Y, Saiura A, Inoue Y, Ishizawa T, et al. Parenchymal-sparing hepatectomy does not increase intrahepatic recurrence in patients with advanced colorectal liver metastases. Ann Surg Oncol 2016;23:3718–3726.
Memeo R, de Blasi V, Adam R, Goere D, Azoulay D, et al, French Colorectal Liver Metastases Working Group AFdC. Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: a propensity score matching analysis. HPB (Oxford) 2016;18:781–790.
Donadon M, Cescon M, Cucchetti A, Cimino M, Costa G, et al. Parenchymal-sparing surgery for the surgical treatment of multiple colorectal liver metastases is a safer approach than major hepatectomy not impairing patients' prognosis: A Bi-institutional propensity score-matched analysis. Dig Surg 2018;35:342–349.
Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, et al. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery 2017;161:332–340.
Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, et al. Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol 2015;22:4158–4165.
Brudvik KW, Jones RP, Giuliante F, Shindoh J, Passot G, et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg 2019;269:120–126.
Shindoh J, Makuuchi M, Matsuyama Y, Mise Y, Arita J, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol 2016;64:594–600.
Vigano L, Costa G, Toso C, Cimino M, Andres A, et al. “Precision Surgery” for colorectal liver metastases: Is the time ripe? Ann Surg 2018; https://doi.org/10.1097/SLA.0000000000002855
Brudvik KW, Vauthey JN. Surgery: KRAS mutations and hepatic recurrence after treatment of colorectal liver metastases. Nat Rev Gastroenterol Hepatol 2017;14:638–639.
Vigano L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 2013;258:731–740.
Kokudo N, Miki Y, Sugai S, Yanagisawa A, Kato Y, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002;137:833–840.
Financial Support
This study was supported by the National Cancer Institute under award number P30 CA016672, which supports the MD Anderson Cancer Center Clinical Trials Support Resource.
Author information
Authors and Affiliations
Contributions
Conception/design: KJ, TJV, EAV, MO, TEN, and JNV; data acquisition: KJ, TJV, MO, YSC, CWT, TAA, and JNV; data analysis: KJ, TJV, MO, and EAV; data interpretation: KJ, TJV, EAV, MO, TEN, CWT, JEL, and JNV; drafting: KJ, TJV, EAV, MO, TEN, and JNV; revising: KJ, TJV, EAV, TEN, YSC, CWT, TAA, JEL, and JNV.
Corresponding author
Ethics declarations
Oral Presentation
Presented at a Plenary Session at the 60th Annual Meeting of the Society for Surgery of the Alimentary Tract, May 2019, San Diego, CA.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Supplementary Table 1
(DOCX 22 kb)
Supplemental Figure 1
Overall survival in patients with anatomic (AR) vs non-anatomic resection (NAR) according to RAS mutation status before matching for a) the whole cohort, b) RAS wild-type, and c) RAS mutation and after matching for d) the whole cohort, e) RAS wild-type, and f) RAS mutation. (PPTX 95.3 KB)
Rights and permissions
About this article
Cite this article
Joechle, K., Vreeland, T.J., Vega, E.A. et al. Anatomic Resection Is Not Required for Colorectal Liver Metastases with RAS Mutation. J Gastrointest Surg 24, 1033–1039 (2020). https://doi.org/10.1007/s11605-019-04299-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-019-04299-6